BTIG Expands Healthcare Research Coverage with Biotechnology Analyst Justin Zelin
New York – January 11, 2021 – BTIG announced today that Justin Zelin has joined the firm’s Research and Strategy division as a Director. Mr. Zelin’s research coverage will focus on the biotechnology sector, where he will specialize in cell therapy, targeted oncology, immunology and auto-immune disease therapeutics. He will report to David Lenchus, Director of Research, at BTIG.
“We are thrilled to welcome Justin to BTIG’s Biotechnology Research team,” noted Mr. Lenchus. “His formal training as a scientist, with direct experience working on immuno-oncology and infectious disease therapeutic development, will help uncover important analysis from the fundamentals of companies he covers. Justin’s expansive relationships and rich understanding of the industry offers our clients a unique perspective as they evaluate their investment opportunities.”
Prior to BTIG, Mr. Zelin was a Biotech Equity Research Analyst at B. Riley Securities. Previously, he held biotech equity research associate roles at Canaccord Genuity and SVB Leerink. Earlier in his career, Mr. Zelin worked in both academic and industry labs including Agenus, Harvard University and Brigham and Women’s Hospital. He was also a member of Harvard University’s teaching staff for more than five years. Mr. Zelin earned a master’s degree in biotechnology and a bachelor’s degree in biology from Harvard University.
Mr. Zelin joins BTIG’s established team of experienced, publishing Biotechnology Analysts including Bert Hazlett, Thomas Shrader, PhD, CFA, and Julian Harrison. Biotechnology continues to be a core area of growth for the firm which increasingly offers differentiated and actionable expertise for clients.
BTIG Research and Strategy provides comprehensive reports, industry observations and other insights for clients. The team’s sector focus includes consumer, energy, financials, healthcare, real estate, shipping, as well as technology, media and telecommunications.
BTIG is a global financial services firm specializing in institutional trading, investment banking, research and related brokerage services. With an extensive global footprint and more than 650 employees, BTIG, LLC and its affiliates operate out of 18 cities throughout the U.S., and in Europe, Asia and Australia. BTIG offers execution, expertise and insights for equities, equity derivatives, ETFs and fixed income, currency and commodities (futures, interest rates, credit, and convertible and preferred securities). The firm’s core capabilities include global execution, portfolio, electronic and outsource trading, transition management, investment banking, prime brokerage, capital introduction, corporate access, research and strategy, commission management and more. Disclaimer: https://www.btig.com/disclaimer.